Anzeige
Mehr »
Login
Samstag, 27.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Nurexone Biologic: Jetzt diese wirklich einzigartige Chance ergreifen?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
21 Leser
Artikel bewerten:
(0)

FoxHollow Technologies Schedules Earnings Conference Call for August 8, 2007


REDWOOD CITY, Calif., Aug. 1 /PRNewswire-FirstCall/ -- FoxHollow Technologies announced that it will report its financial results for the second quarter 2007 after market close on Wednesday, August 8, 2007. The company will hold a conference call the same day at 2 p.m., Pacific Time (5 p.m. Eastern Time). The call will be hosted by Dr. John B. Simpson, FoxHollow's Chief Executive Officer and Matt Ferguson, Chief Financial Officer.

The teleconference can be accessed via the investor relations section of the company's website at http://investor.foxhollowtech.com/ or by calling 800-322-9079 (domestic), or 973-582-2717 (international). Please dial in or access the website 10 to 15 minutes prior to the beginning of the call.

A replay of the conference call will be available at 8:00 p.m. Eastern Time through 11:59 p.m. Eastern Time, August 20, 2007, and may be accessed by dialing 877-519-4471 (domestic), or 973-341-3080 (international), passcode 9076324. An online archive of the webcast will be available for a minimum of two months by accessing the investor relations portion of the company's website at http://investor.foxhollowtech.com/.

About FoxHollow Technologies

FoxHollow Technologies, Inc. develops and markets minimally invasive devices for the removal of plaque and thrombus for the treatment of peripheral artery disease (PAD). PAD results from plaque that accumulates in the arteries and blocks blood flow in the legs. These blockages can result in severe pain for patients and very limited physical mobility. The company's SilverHawk Plaque Excision System is a minimally invasive method of removing the obstructive plaque and restoring blood flow to the legs and feet. The company's Rinspirator thrombectomy system removes thrombus, or blood clots, from occluded arteries in patients suffering from PAD or coronary artery disease (CAD). For more information, please visit our website at http://www.foxhollowtech.com/.

Further information on FoxHollow's business and financial results are detailed in its filings with the Securities and Exchange Commission, including the company's most recent Quarterly Report on Form 10-Q as filed on May 9, 2007.
Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2007 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.